Prevenar 13® NHS

Current Recommendations in the UK

The Department of Health and Social Care recommends Prevenar 13® for particular groups:

Childhood Immunisation Programme 

  • The pneumococcal vaccine programme for babies has been in place since 2006. Prevenar 13® replaced Prevenar (PCV7) in 2010.1
  • It has been estimated that almost 40,000 cases of Invasive Pneumococcal Disease (IPD) have been prevented since the introduction of the pneumococcal conjugate vaccine programme.1
  • The Prevenar 13® vaccine is part of the childhood immunisation programme and should be administered according to the UK schedule.2
  • Infants who receive a first dose of Prevenar 13® should complete the vaccination course with Prevenar 13®.3,4
  • Prevenar 13® can be co-administered with other routine paediatric vaccines administered as part of the UK national immunisation programme.2,3
  • Prevenar 13® is also recommended for children from their first birthday up until their second birthday who have an unknown or incomplete vaccination history.5


Clinical Risk Groups

In addition to the childhood immunisation programme, the green book recommends Prevenar 13® for:6

  • Children under 10 years of age in certain clinical risk groups.* 
  • Children 10 years onwards and adults in specific clinical risk groups. 


People Living with HIV (PLWHIV)

  • The green book refers Healthcare professionals to The British HIV Association (BHIVA) guidance for guidance on the vaccination of adults living with HIV.7  
  • The British HIV Association (BHIVA) guidance recommends all adults who are HIV positive should receive a single dose of Prevenar 13®, irrespective of CD4 cell count and antiretroviral therapy (ART).
  • The green book outlines that infants living with HIV should receive Prevenar 13® as part of the routine childhood immunisation programme. In addition children living with HIV aged 2 to 10 years of age who are unimmunised or partially immunised against pneumococcal disease should receive a single dose of Prevenar 13®.6

For an in-depth pneumococcal immunisation schedule for individuals in clinical risk groups please visit chapter 25 of the green book.


  • For the childhood immunisation schedule, stock comes from ImmForm.  
  • For clinical risk groups outlined in chapter 25 of the green book, ImmForm should not be used. Prevenar 13® should be ordered directly from Alliance Healthcare (ImmForm stock is reserved for the infant National Immunisation Programme).

For more information or supply enquiries contact our Pfizer Vaccines team on: 0800 089 4033 or email [email protected]

*Asplenia, splenic dysfunction, complement disorder or severely immunocompromised.  Examples of severely immunocompromised include bone marrow transplant patients, patients with acute and chronic leukaemia, multiple myeloma or genetic disorders affecting the immune system (such as IRAK-4, NEMO).6

Bone marrow transplant patients, patients with acute and chronic leukemia, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement deficiency).6



  1. Ladhani S, Collins S, Djennad A et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. The Lancet Infectious Diseases. 2018;18(4):441-451.
  2. Routine Childhood Immunisation Programme. Last accessed June 2020.
  3. Prevenar13® Summary of Product Characteristics. accessed June 2020.
  4. Public Health England Changes to the Infant Pneumococcal Conjugate Vaccine Schedule. Last accessed June 2020.
  5. Public Health England. Vaccination of individuals uncertain or incomplete immunisation status. Last accessed June 2020.
  6. Greenbook, chapter 25, Last accessed June 2020.
  7. Greenbook, chapter 7, Last accessed June 2020.
  8. BHIVA. British HIV Association guidelines on the use of vaccines in HIV-positive adults. 2015. Available from: Last accessed June 2020.

Prescribing Information
Prevenar 13® prescribing information.


PP-PNA-GBR-0416.  July 2020